Second-Line Progestogen Options

Introduction to Alternatives

Medroxyprogesterone acetate (MPA) 10 mg daily for 12-14 days monthly or 2.5-5 mg daily is a widely available and evidence-based alternative to Prometrium, according to the guidelines from the society that published in Blood Reviews 1
Norethindrone acetate 1 mg daily offers a superior cardiovascular and metabolic profile compared to MPA, as recommended by the society that published in Blood Reviews 1

MPA remains the most commonly prescribed alternative due to extensive safety data and widespread availability, despite its less favorable metabolic profile compared to natural progesterone, as stated by the society that published in Blood Reviews 1
MPA has documented adverse effects on lipid profiles, vasomotion, and carbohydrate metabolism compared to natural progesterone, according to the society that published in Blood Reviews 1

Norethindrone acetate 1 mg daily offers better metabolic and cardiovascular outcomes than MPA while maintaining excellent endometrial protection, as recommended by the society that published in Blood Reviews 1

Dydrogesterone is listed among ESHRE-recommended progestogens, though evidence in premature ovarian insufficiency populations is limited, as stated by the society that published in Blood Reviews 1
Dydrogesterone has enhanced oral bioavailability compared to natural progesterone, according to the society that published in Blood Reviews 1
Dydrogesterone lacks robust endometrial safety data in POI populations, as noted by the society that published in Blood Reviews 1

The levonorgestrel intrauterine system is particularly useful for patients experiencing systemic progestogen side effects, as recommended by the society that published in Blood Reviews 1

Natural progesterone and lower-dose norethindrone acetate are preferable to MPA due to their better cardiovascular safety profiles, as stated by the society that published in Blood Reviews 1

The American College of Obstetricians and Gynecologists recommends oral medroxyprogesterone acetate 10 mg daily for 12-14 days every 28 days when using transdermal 17β-estradiol patches releasing 50-100 μg daily 2

A patient using a 50 mcg estradiol patch requires proportionally more progestogenic opposition, as a study showed that vaginal progesterone 100 mg twice weekly achieved acceptable bleeding patterns and atrophic endometrium with only a 25 μg/day estradiol patch 3

Oral micronized progesterone 100-200 mg daily continuously provides full endometrial protection in the long term, whereas sequential regimens may have insufficient protection 2

Perform baseline endometrial ultrasound to document endometrial thickness, and consider annual endometrial thickness monitoring if using off-label vaginal regimens 3
Baseline endometrial ultrasound is also recommended by Blood Reviews 4

The levonorgestrel intrauterine system delivers progestogen directly to the uterus, providing reliable endometrial protection with fewer systemic adverse effects than oral or vaginal routes, as recommended by the British Menopause Society 5, 6
The British Menopause Society emphasizes that progestogen must be delivered for at least the same duration as the luteal phase (12-14 days monthly in sequential regimens) in recommended doses to protect against endometrial hyperplasia and cancer 5, 6

For patients requiring menstrual suppression during chemotherapy or thrombocytopenia, norethisterone 5-15 mg daily continuously may be used, but higher doses carry thrombotic risk, and medroxyprogesterone acetate may be preferable in patients with high venous thromboembolism risk, and continuous use should be limited to <6 months to prevent meningioma risk 7
Norethisterone acetate 1 mg daily provides adequate endometrial protection with a better cardiovascular profile than medroxyprogesterone acetate, and medroxyprogesterone acetate 10 mg for 12-14 days monthly remains the gold standard for proven endometrial protection 8

For young women requiring hormone replacement, norethisterone acetate 1 mg daily offers a superior cardiovascular and metabolic profile compared to medroxyprogesterone acetate while maintaining bone mineral density, and natural micronized progesterone remains the preferred option when available due to the most favorable safety profile 8
For patients with thrombotic risk, therapeutic doses of norethisterone may increase venous thromboembolism risk, and consider medroxyprogesterone acetate depot or levonorgestrel IUS as safer alternatives 7